Skip to content
PHIOPhio Pharmaceuticals Corp.

Earnings

When Phio Pharmaceuticals Corp. reports, what it reported each quarter, and how the stock took the results.

61 quarters. Jun 30, 2011 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 4, after the close

Thu, Mar 4, 2027in 107 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 19 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2020 n/m, Q3 2020 n/m, Q2 2020 n/m, Q1 2020 −100.0%
Net income
-$2.37M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q2 2025 n/m, Q1 2025 n/m, Q3 2024 n/m, Q2 2024 n/m

Quarter by quarter

Q4 2023—

Latest results

  1. Q3 2026Nov 5, 2026, after the closeThe release4.7%by the close of Nov 6
    Revenue
    —
    —
    Net income
    -$4.16M
    N/M
    EPS
    —
    —
  2. Q2 2026Aug 6, 2026, after the closeThe release0.0%by the close of Aug 7
    Revenue
    —
    —
    Net income
    -$4.14M
    N/M
    EPS
    —
    —
  3. Q1 2026May 7, 2026, after the closeThe release4.4%by the close of May 8
    Revenue
    —
    —
    Net income
    -$4.00M
    N/M
    EPS
    —
    —
  4. Q4 2025Mar 5, 2026, after the closeThe release0.9%by the close of Mar 6
    Revenue
    —
    —
    Net income
    -$2.37M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · after-hoursNov 5, 202636 d10-Q———4.7%
Q2 2026Jun 30, 2026Aug 6, 2026 · after-hoursAug 6, 202637 d10-Q———0.0%
Q1 2026Mar 31, 2026May 7, 2026 · after-hoursMay 7, 202637 d10-Q———4.4%
FY 2025
Q4 2025derivedDec 31, 2025Mar 5, 2026 · after-hoursMar 5, 202664 d10-K———0.9%
Q3 2025Sep 30, 2025Nov 13, 2025 · after-hoursNov 13, 202544 d10-Q———9.1%
Q2 2025Jun 30, 2025Aug 14, 2025 · after-hoursAug 14, 202545 d10-Q——-$0.450.5%
Q1 2025Mar 31, 2025May 15, 2025 · after-hoursMay 15, 202545 d10-Q——-$0.41+3.4%
FY 2024
Q4 2024derivedDec 31, 2024Mar 31, 2025 · after-hoursMar 31, 202590 d10-K———5.4%
Q3 2024Sep 30, 2024Nov 14, 2024 · after-hoursNov 14, 202445 d10-Q——-$1.544.7%
Q2 2024Jun 30, 2024Aug 14, 2024 · after-hoursAug 14, 202445 d10-Q——-$3.62+15.1%
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 9, 202439 d10-Q——-$0.4713.1%
Earlier years, FY 2011 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026035280
10-QAug 6, 2026026271
10-QMay 7, 2026015604
10-KMar 5, 2026007078
10-QNov 13, 2025034857
10-QAug 14, 2025006174
10-QMay 15, 2025003719
10-KMar 31, 2025002134
10-QNov 14, 2024008120
10-QAug 14, 2024005706

Provenance

ProvenanceData status and checks

Phio Pharmaceuticals Corp. · CIK 1533040 · Engraved from SEC EDGAR